

HIV DRUG RESISTANCE

CONCEPT NOTE

SURVEILLANCE OF HIV DRUG RESISTANCE IN ADULTS INITIATING ANTIRETROVIRAL THERAPY (PRE-TREATMENT HIV DRUG RESISTANCE)

JULY 2014



SURVEILLANCE OF HIV DRUG RESISTANCE IN ADULTS INITIATING ANTIRETROVIRAL THERAPY (PRETREATMENT HIV DRUG RESISTANCE)

JULY 2014

WHO Library Cataloguing-in-Publication Data

Surveillance of HIV drug resistance in populations initiating antiretroviral therapy
(pre-treatment HIV drug resistance)

1. Anti-HIV agents – therapeutic use. 2. Drug resistance, Viral – drug effects. 3. HIV infections – epidemiology. 4. HIV infections – drug therapy 5. Population surveillance. I. World Health Organization.

ISBN 978 92 4 150719 6

(NLM classification: QV 268.5)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Layout by L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland.

TABLE OF CONTENTS

Acknowledgments	3
Acronmys	3
Background	4
1. Introduction	5
2. Survey purpose and overview	5
3. Survey outcomes	6
4. Overview of methods	7
4.1 Survey approach	7
4.2 How to select clinics	7
4.2.1 Sampling very small or difficult-to-access clinics	7
4.2.2 Regional representation	8
4.2.3 Countries with many ART clinics	8
4.3 Patient eligibility criteria	8
4.3.1 Inclusion criteria	8
4.3.2 Exclusion criteria	8
4.4 Defining the survey sample size	8
4.4.1 Assumptions	8
4.4.2 Sample size calculations	9
4.4.3 Countries sampling all clinics where ART is initiated	11
4.5 Laboratory methods	11
4.5.1 Specimen collection, handling, processing and tracking	11
4.5.2 HIVDR genotyping and quality assurance of sequences	11
5. Implementation considerations	12
5.1 Duration of the survey, patient screening and sampling	12
5.2 List of variables to be collected	13
5.2.1 Patient-level information	13
5.2.2 Clinic-level information	13
5.2.3 Survey-level information	14
5.3 Patient under-enrolment	14
5.4 Repeating the survey	14
5.5 Tools for country adaptation	14
5.6 Combining pre-treatment and acquired drug resistance surveys	14
6. Data analysis	15

ANNEXES	16
Annex 1.1: Selecting the clinics to survey	16
Annex 1.2: Guaranteeing representation from all regions	16
Annex 1.3: Stratification	18
Annex 1.4: Data analysis plan	20
Annex 1.5: Reporting of HIVDR data	24
Statistical Appendix	25
1. Sample size calculations	25
2. Calculating the contribution to the design effect due to clustering of the outcome by clinic	26
3. Calculating the contribution to the design effect due to imperfect weighting information	27
4. Other sources of design effect	28
5. Calculating the sample size	28
6. Incorporating the finite population correction	29
7. Sample size calculations when all clinics are sampled	29
8. Data analysis	30

ACKNOWLEDGMENTS

The work was led by Silvia Bertagnolio (World Health Organization), Jhoney Barcarolo (consultant) and Michael Jordan (Tufts University School of Medicine, USA). Statistical Methods were developed by Natalie Exner Dean and Marcello Pagano (Harvard University, USA). Natalie Exner Dean wrote the statistical annexes and analysis plan. The concept note received substantial technical inputs and revisions by the HIVResNet Core Group (Emiliano Bissio, Argentina; Avelin Aghokeng, Cameroun; Elliot Raizes, USA; and Andrea De Luca, Italy).

Jos Perriens, coordinator of the Technologies and Commodities Team at the HIV Department, World Health Organization, provided overall supervision. We thank the United States Centers for Disease Control and Prevention, Atlanta, USA and the President's Emergency Plan for AIDS Relief (PEPFAR) HIV Drug Resistance working group for their critical inputs to the document.

We are most grateful to the HIVResNet Steering Group (Chunfu Yang, USA; Chris Archibald, Canada; Achara Teeraratkul,

Thailand; Avelin Aghokeng, Cameroun; AM.J. Wensing, the Netherlands; Christopher Duncombe, USA; Kerry Dierberg, USA; Do Thi Nhan, Vietnam; Emiliano Bissio, Argentina; Elliot Raizes, USA; Jonathan Shapiro, Israel; Natalia Nizova, Ukraine; Robert W. Shafer, USA; Wilford Kirungi, Uganda; Zhang Fujie, China; Tobias Rinke de Wit, the Netherlands; and Sergio Carmona, South Africa) for their strategic advice. We are also grateful to the contributions provided by WHO staff from regional and country offices.

Additionally, development of this guidance document benefitted greatly from inputs received from country ART programme managers and country representatives attending WHO regional workshops conducted in 2013 in Beijing, China; Brasilia, Brazil; Montpellier, France; Addis Ababa, Ethiopia; and Cape Town, South Africa. WHO is grateful to Amandine Cournil, Montpellier, France, for her review of the statistical annexes. Development and publication of this guidance was supported by the Bill and Melinda Gates Foundation (#38180); we are sincerely grateful for their support.

ACRONMYS

ADR	acquired HIV drug resistance
AIDS	acquired immunodeficiency syndrome
ART	antiretroviral therapy
ARV	antiretroviral drug
ATV/r	atazanavir/ritonavir
AZT	zidovudine (also ZDV)
DEFF	design effect
DBS	dried blood spot
DRV/r	darunavir/ritonavir
EFV	efavirenz
HIV	human immunodeficiency virus
ICC	intracluster correlation coefficient
HIVDR	HIV drug resistance
INI	integrase inhibitor
LPV/r	lopinavir/ritonavir
mL	milliliter
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor

N(t)RTI	nucleotide reverse transcriptase inhibitor
NVP	nevirapine
PDR	pre-treatment HIV drug resistance
PEP	post exposure prophylaxis
PEPFAR	President's Emergency Plan for AIDS Relief
PI	protease inhibitor
PPS	probability proportional to size
PPPS	probability proportional to proxy size
PR	protease region
PrEP	pre-exposure prophylaxis
RT	reverse transcriptase region
SI	sampling interval
SID	survey identification number
VL	viral load
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNGASS	United Nations General Assembly Special Session
WHO	World Health Organization

BACKGROUND

HIV Drug Resistance (HIVDR) emerges when HIV replicates in the presence of antiretroviral drugs. If HIV drug resistance becomes widespread, the drugs currently used to treat HIV infection may become ineffective. To date, levels of HIVDR in countries scaling up antiretroviral therapy (ART) remain manageable. However, resistance is slowly increasing. In East Africa, resistance rates of 10% to non-nucleoside drugs (such as nevirapine and efavirenz) have been recently described.


To maximize the long-term effectiveness of first-line ART and ensure the sustainability of ART programmes, it is essential to minimize the further spread of HIV drug resistance. Even in settings with optimal ART programme management, some degree of HIVDR is expected to emerge in populations on ART, and some HIVDR is expected to be transmitted to previously uninfected individuals. Therefore, WHO recommends that HIV treatment scale-up should always be accompanied by a robust assessment of drug resistance emergence and transmission. WHO's HIVDR monitoring and surveillance strategy is composed of five key elements:

- i. Monitoring of Early Warning Indicators of HIV drug resistance
- ii. Surveillance of HIVDR in recently-infected adult populations (transmitted HIVDR)
- iii. Surveillance of pre-treatment HIVDR in adult populations initiating ART (pre-treatment HIVDR)
- iv. Surveillance of acquired HIVDR in populations of adults and children receiving ART (acquired HIVDR)
- v. Surveillance of HIV drug resistance in treatment-naive children less than 18 months of age

WHO's HIVDR Surveillance and Monitoring Strategy is a critical component of the public health approach to ART delivery. By obtaining population-level data on HIVDR in different populations, its various elements can inform programme-level decision making regarding, for example, optimal first and second lines, for both children and adults.

This document describes methods to assess HIVDR in adult populations about to initiate ART (surveillance of pre-treatment HIVDR).

Figure 1. HIV Drug Resistance Surveillance and Monitoring Strategy



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27806

